title: Brain levels of neuropeptides in human chronic methamphetamine users.
abstract: Animal data show that neuropeptide systems in the dopamine-rich brain areas of the striatum (caudate, putamen, and nucleus accumbens) are influenced by exposure to psychostimulants, suggesting that neuropeptides are involved in mediating aspects of behavioral responses to drugs of abuse. To establish in an exploratory study whether levels of neuropeptides are altered in brain of human methamphetamine users, we measured tissue concentrations of dynorphin, metenkephalin, neuropeptide Y, neurotensin, and substance P in autopsied brains of 16 chronic methamphetamine users and 17 matched control subjects. As expected, levels of most neuropeptides were enriched in dopamine-linked brain regions such as the nucleus accumbens and striatum of normal human brain. In contrast to animal findings of increased neuropeptide levels following short-term methamphetamine exposure, striatal neuropeptide concentrations were either normal or moderately decreased in the methamphetamine users. In other examined dopamine-poor cortical and subcortical brain areas, neuropeptide levels were generally either normal or variably reduced. Although the neuropeptide differences might be explained by methamphetamine-induced damage to neuropeptide-containing neurons, our human data are consistent with the possibility that, at least in the human striatum, long-term methamphetamine exposure leads to an adaptive process that is distinct from that which increases neuropeptide levels after acute methamphetamine exposure.
authors: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA. paul.frankel@pharm.utah.edu
authors: Paul S
authors: PS
authors: Frankel
authors: Mario E
authors: ME
authors: Alburges
authors: Lloyd
authors: L
authors: Bush
authors: Glen R
authors: GR
authors: Hanson
authors: Stephen J
authors: SJ
authors: Kish
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008694:Methamphetamine; D009479:Neuropeptides / Q000378:metabolism*; D011180:Postmortem Changes; D011863:Radioimmunoassay / Q000379:methods; D018709:Statistics, Nonparametric; D019966:Substance-Related Disorders / Q000209:etiology / Q000378:metabolism / Q000473:pathology*
chemical_list: D009479:Neuropeptides; D008694:Methamphetamine
references: J Neurochem. 2000 May;74(5):2120-6
references: 10800957
references: Forensic Sci Int. 2001 Feb 15;116(2-3):163-9
references: 11182268
references: J Neurochem. 2001 Feb;76(3):721-9
references: 11158242
references: Neuroscience. 2001;102(4):843-51
references: 11182247
references: Am J Psychiatry. 2001 Mar;158(3):377-82
references: 11229977
references: Curr Mol Med. 2002 Nov;2(7):667-76
references: 12420805
references: Psychol Med. 2003 Nov;33(8):1407-14
references: 14672249
references: Brain. 2004 Feb;127(Pt 2):363-70
references: 14645148
references: Eur J Pharmacol. 1991 Feb 14;193(3):367-70
references: 1675997
references: Trends Neurosci. 1992 Apr;15(4):133-9
references: 1374971
references: Neuropeptides. 1992 Jul;22(3):175-83
references: 1436404
references: Eur J Pharmacol. 1992 Nov 3;222(1):7-12
references: 1361442
references: Synapse. 1993 Apr;13(4):357-69
references: 7683144
references: Neuroscience. 1993 Aug;55(3):833-47
references: 8105419
references: Eur J Pharmacol. 1994 Jan 14;251(2-3):191-9
references: 7908639
references: Nat Med. 1996 Jun;2(6):699-703
references: 8640565
references: Biol Pharm Bull. 1996 Mar;19(3):369-74
references: 8924903
references: J Pharmacol Exp Ther. 1996 Aug;278(2):547-54
references: 8768703
references: Brain Res. 1996 May 20;721(1-2):196-203
references: 8793101
references: Brain Res Bull. 1997;42(3):211-9
references: 8995332
references: Exp Neurol. 1998 Jul;152(1):41-9
references: 9682011
references: Exp Brain Res. 1998 Nov;123(1-2):60-76
references: 9835393
references: J Pharmacol Exp Ther. 1999 Mar;288(3):1160-6
references: 10027854
references: Mol Psychiatry. 1999 Jan;4(1):26-32
references: 10089005
references: Neuropsychopharmacology. 1999 Jun;20(6):565-81
references: 10327426
references: Am J Psychiatry. 2005 Aug;162(8):1403-13
references: 16055761
references: Eur J Pharmacol. 2005 Oct 17;522(1-3):47-54
references: 16199030
references: Biol Psychiatry. 2005 Nov 15;58(10):770-8
references: 16095568
references: Nat Neurosci. 2006 Feb;9(2):205-11
references: 16415864
references: Neuropharmacology. 2000 Jul 24;39(10):1880-92
references: 10884569
references: J Neurochem. 2004 Jun;89(6):1396-408
references: 15189342
references: J Forensic Sci. 2004 Sep;49(5):1106-12
references: 15461119
references: Nature. 1981 May 7;291(5810):73-6
references: 7231526
references: Psychopharmacology (Berl). 1982;78(1):76-80
references: 6815700
references: Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(1):91-5
references: 2581284
references: J Pharmacol Exp Ther. 1987 May;241(2):443-7
references: 3572804
references: J Biol Chem. 1988 Feb 5;263(4):1719-25
references: 3276675
references: Eur J Pharmacol. 1988 Mar 15;147(3):411-20
references: 2454197
references: Eur J Pharmacol. 1988 Oct 11;155(1-2):11-8
references: 2907484
references: J Comp Neurol. 1990 May 15;295(3):339-69
references: 1693632